Literature DB >> 11719267

New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins.

J Ko1, S Ou, P H Patterson.   

Abstract

We produced eight anti-huntingtin (Htt) monoclonal antibodies (mAbs), several of which have novel binding patterns. Peptide array epitope mapping shows that mAbs MW1-6 specifically bind the polyQ domain of Htt exon 1. On Western blots of extracts from mutant Htt knock-in mouse brain and Huntington's disease lymphoblastoma cell lines, MW1-5 all strongly prefer to bind to the expanded polyQ repeat form of Htt, displaying no detectable binding to normal Htt. These results suggest that the polyQ domain can assume different conformations that are distinguishable by mAbs. This idea is supported by immunohistochemistry with wild type (WT) and mutant Htt transgenic mouse (R6) brains. Despite sharing the same epitope and binding preferences on Western blots, MW1-5 display distinct staining patterns. MW1 shows punctate cytoplasmic and neuropil staining, while MW2-5 strongly stain the neuronal Golgi complex. MW6, in contrast, stains neuronal somas and neuropil. In addition, despite their preference for mutant Htt on blots, none of these mAbs show enhanced staining of R6 brains over WT, and show no binding of the Htt-containing nuclear inclusions in R6 brains. This suggests that in its various subcellular locations, the polyQ domain of Htt either takes on different conformations and/or is differentially occluded by Htt binding proteins. In contrast to MW1-6, MW7, and 8 can differentiate transgenic from WT mice by staining nuclear inclusions in R6/2 brain; MW8 displays no detectable staining in WT brain and stains only inclusions in R6/2 brain. Epitope mapping reveals that MW7 and 8 specifically bind the polyP domains and amino acids 83-90, respectively. As with MW1-6, the epitopes for MW7 and 8 are differentially available in the various subcellular compartments where Htt is found.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719267     DOI: 10.1016/s0361-9230(01)00599-8

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  89 in total

1.  Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.

Authors:  Ali Khoshnan; Jan Ko; Paul H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

Review 2.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

3.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

4.  Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure.

Authors:  Clare Peters-Libeu; Jason Miller; Earl Rutenber; Yvonne Newhouse; Preethi Krishnan; Kenneth Cheung; Danny Hatters; Elizabeth Brooks; Kartika Widjaja; Tina Tran; Siddhartha Mitra; Montserrat Arrasate; Luis A Mosquera; Dean Taylor; Karl H Weisgraber; Steven Finkbeiner
Journal:  J Mol Biol       Date:  2012-01-28       Impact factor: 5.469

5.  Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.

Authors:  Jung Hae Yoon; Eric Johnson; Rui Xu; Laura T Martin; Paul T Martin; Federica Montanaro
Journal:  J Proteome Res       Date:  2012-07-30       Impact factor: 4.466

6.  Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis.

Authors:  Jonathan A Sayer; Maria Manczak; Lakshmi Akileswaran; P Hemachandra Reddy; Vincent M Coghlan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

7.  A toxic mutant huntingtin species is resistant to selective autophagy.

Authors:  Yuhua Fu; Peng Wu; Yuyin Pan; Xiaoli Sun; Huiya Yang; Marian Difiglia; Boxun Lu
Journal:  Nat Chem Biol       Date:  2017-09-04       Impact factor: 15.040

8.  The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease.

Authors:  Elisabeth Singer; Lilit Hunanyan; Magda M Melkonyan; Jonasz J Weber; Lusine Danielyan; Huu Phuc Nguyen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-12

9.  Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.

Authors:  Christian Landles; Kirupa Sathasivam; Andreas Weiss; Ben Woodman; Hilary Moffitt; Steve Finkbeiner; Banghua Sun; Juliette Gafni; Lisa M Ellerby; Yvon Trottier; William G Richards; Alex Osmand; Paolo Paganetti; Gillian P Bates
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

10.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.